Discovering new medicines takes years and is marred by an astronomical failure rate. The Nobel Prize-winning head of Alphabet’s AI lab says the technology will soon trim that time to under a year https://t.co/yMO6xfKz86 ...

Core Insights - Absci Inc. has partnered with Oracle Corporation and AMD to enhance its generative AI-driven drug discovery capabilities [1][2] - The collaboration aims to streamline infrastructure and accelerate biologics design cycles through advanced AI technologies [1][2] Group 1: Collaboration and Technology - Absci's generative AI Drug Creation Platform utilizes Oracle Cloud Infrastructure (OCI) and AMD's hardware to improve drug discovery processes [1] - The partnership allows for large-scale molecular-dynamics simulations and comprehensive antibody design, significantly speeding up development and operations [2] Group 2: Infrastructure and Performance - The integration of fifth-generation AMD EPYC processors and RDMA cluster networking in OCI's bare metal instances provides the necessary low-latency networking and throughput for extensive model training [3] - Direct access to AMD GPUs in a flat-network supercluster has minimized hypervisor overhead and reduced inter-GPU latency to as low as 2.5 microseconds, enhancing data streaming capabilities [4] Group 3: Market Reaction - Following the announcement, Absci's stock price increased by 10.50%, reaching $2.63 [5]

Core Insights - Absci announced a collaboration with Oracle Cloud Infrastructure and AMD to enhance its AI-driven drug discovery initiatives [2] Group 1: Collaboration Details - The partnership will leverage Oracle's AI infrastructure and AMD's technology to accelerate drug discovery processes [2]

Core Insights - Absci collaborates with Oracle Cloud Infrastructure (OCI) and AMD to enhance its generative AI-driven drug discovery platform, aiming to accelerate biologics design cycles and reduce costs [1][2][3] Company Overview - Absci is a clinical-stage biotech company focused on advancing novel therapeutics using generative AI, with a mission to create better biologics for patients more quickly [5] - The company utilizes an Integrated Drug Creation™ platform that combines advanced AI models with a synthetic biology data engine, facilitating rapid design and validation of therapeutics [5] Technology and Infrastructure - Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows, enabling large-scale molecular-dynamics simulations and end-to-end antibody design [2][3] - The collaboration leverages OCI's bare metal instances powered by 5th Generation AMD EPYC™ processors and ultrafast RDMA networking, providing low-latency networking and high throughput for model training and simulations [3][4] - The integration of AMD's next-generation Instinct™ MI355X GPUs further enhances the performance and scalability of Absci's AI Drug Creation Platform [2][4] Industry Impact - The partnership between Absci, OCI, and AMD exemplifies how AI can transform drug discovery processes, accelerating the development of novel therapeutics [4] - The collaboration aims to push the boundaries of biologics design by combining cutting-edge AI models with high-performance infrastructure [3][4]

Drug Discovery Process - Traditional drug discovery is lengthy and costly, taking 10-15 years and billions of dollars to bring a single drug to market [4][5] - AI can accelerate drug discovery and reduce costs by using machine learning and deep learning algorithms [6] - AI-driven virtual screening can identify potential drug candidates from vast chemical spaces, reducing the number of candidates for lab validation from millions to 50-100 [8][9][10] AI Applications in Drug Development - AI can assist in target identification by analyzing data to determine connections with specific indications [19] - AI can predict toxicology, efficacy, stability, and pharmacokinetics of drug candidates [20] - AI can aid in patient stratification during clinical studies by analyzing patient data (genetic information, images, physical information) to group patients who may or may not benefit from the drug [13][14] Clinical Trials and Regulatory Approval - Only 10% of drugs entering clinical studies are successful, highlighting the need for optimized clinical trial design [15] - AI can be used for risk management in clinical trials, predicting risk factors and adapting protocols based on results [17] - AI can assist in preparing FDA submissions and communicating drug information to patients using large language models [17][18]

Company Overview - PreveCeutical Medical Inc. is a health sciences company focused on developing innovative preventive and curative therapies using organic and nature-identical products [5] - The company has five research and development programs targeting diabetes, obesity, and other health issues, including dual gene therapy and non-addictive analgesic peptides [5] Leadership Appointment - BioGene Therapeutics Inc., a wholly owned subsidiary of PreveCeutical, appointed Dr. Francis Tavares as Chief Technology Officer effective August 19, 2025 [1][4] - Dr. Tavares has extensive experience in the biopharmaceutical industry, previously serving as President, CEO, and Founder of ChemoGenics BioPharma, and has a strong background in drug discovery and medicinal chemistry [2][3] Dr. Tavares' Contributions - Dr. Tavares has a PhD in Organic Chemistry and has led the development of significant drug candidates, including Trilaciclib and Lerociclib, demonstrating a successful track record in advancing drug candidates to clinical trials [3] - His appointment is expected to enhance BioGene's capabilities in drug discovery and product commercialization, benefiting both patients and investors [4] BioGene Therapeutics Inc. Overview - BioGene is focused on advancing innovative therapies in metabolic health and gene-based treatments, with a subsidiary in Australia that leverages a 43.5% R&D tax cashback incentive [6] - The company is engaged in research aimed at addressing the global diabetes and obesity crisis through gene therapy-based approaches [6]

Core Viewpoint - Marvel Biosciences Corp. has received a patent for its lead asset MB-204, which is aimed at treating autism spectrum disorder and related conditions, highlighting the company's commitment to addressing significant unmet medical needs in this area [1][3]. Company Overview - Marvel Biosciences Corp. is a Calgary-based biotechnology company focused on developing new treatments for neurological diseases and neurodevelopmental disorders, with MB-204 being a fluorinated derivative of the approved Parkinson's drug Istradefylline [4]. - The company is exploring MB-204's potential in treating conditions such as autism, depression, Alzheimer's disease, and rare disorders like Rett syndrome and Fragile X syndrome [5]. Product Development - MB-204 has shown strong preclinical efficacy across multiple models of autism, Rett syndrome, and depression, and is prepared to enter Phase 1 clinical trials [2]. - The patent granted by the China National Intellectual Property Administration (CNIPA) strengthens Marvel's global intellectual property position, particularly in a key market [1][3]. Market Context - With approximately one in 36 children diagnosed with autism, there is a pressing need for innovative treatments, which underscores the importance of advancing MB-204 through clinical trials [3].

Great to have Olympian @chrishoy join our team offsite!His insights on process and ‘marginal gains’ drew a powerful parallel between elite sport and our mission to reimagine drug discovery. Leaving us all inspired and re-energised! 🚀#DrugDiscovery #AIforScience #SirChrisHoy https://t.co/Z2xsuTLJHq ...

Core Insights - XtalPi is expanding its research collaboration with Pfizer to develop a next-generation molecular modeling platform aimed at enhancing drug discovery processes through improved accuracy and speed of AI models [1][3][4] Company Overview - XtalPi Holdings Limited, founded in 2015 by MIT physicists, integrates quantum physics, AI, and robotics to provide innovative R&D solutions across various industries including pharmaceuticals and materials science [5] Collaboration Details - The collaboration will focus on creating more accurate predictive models tailored to Pfizer's proprietary chemical space, enhancing small molecule drug discovery and development [3] - XtalPi will utilize its XFEP platform for parameter customization and Free Energy Perturbation calculations to support Pfizer's drug discovery efforts [3] Technological Advancements - The first-generation XtalPi Force Field (XFF) demonstrated superior performance in predicting small molecule geometry and binding affinity, crucial for drug screening and rational design [2] - The new platform aims to deliver accurate predictive tools with significantly improved throughput, enhancing the efficiency of drug development [1][3]

编辑丨王多鱼 排版丨水成文 生物医学研究是增进人类对健康和疾病的理解、推动药物研发以及提升临床护理水平的基础。 然而，在生物医学实验室中，科研人员往往被复杂的实验方案、庞大的数据库、五花八门的分析工具以及不停更新的海量文献所淹没。生物医学研究日益受到这 些重复且分散的工作流程的制约，让科研人员疲于奔命， 严重减缓了科学发现的速度，限制了科学创新。这凸显了科学界对根本性新方法的迫切需求——一种能 够 有效扩展科学专业知识、简化研究工作流程，并充分释放生物医学研究潜力的全新路径。 2025 年 6 月 2 日， 斯坦福大学 黄柯鑫 、 Serena Zhang 、 王瀚宸 、 屈元昊 、 陆荧洲 等研究人员领衔的团队，联合 Genentech、Arc Institute、 加州大学 旧金山分校及 普林斯顿大学等 多个顶尖研究机构，发布了一款 通用生物医学 AI 智能体 —— Biomni ，该智能体能够自主完成横跨遗传学、基因组学、微生物 学、药理学和临床医学等多个生物医学分支领域的复杂研究任务 。 Biomni 的诞生标志着 AI 在生物医学研究中从"工具使用者"向"自主决策者"的跃迁 。通过将分散的科研资源整 ...